TransCode Therapeutics, Inc. (NASDAQ:RNAZ – Free Report) – Analysts at HC Wainwright issued their FY2029 earnings per share estimates for shares of TransCode Therapeutics in a research report issued to clients and investors on Wednesday, April 16th. HC Wainwright analyst E. Bodnar forecasts that the company will post earnings per share of ($0.18) for the year. HC Wainwright has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for TransCode Therapeutics’ current full-year earnings is ($4.76) per share.
TransCode Therapeutics Trading Down 23.6 %
Shares of RNAZ opened at $0.27 on Thursday. TransCode Therapeutics has a 52-week low of $0.22 and a 52-week high of $66.33. The stock has a 50 day simple moving average of $2.54 and a 200 day simple moving average of $168.66.
TransCode Therapeutics Company Profile
TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.
Read More
- Five stocks we like better than TransCode Therapeutics
- Upcoming IPO Stock Lockup Period, Explained
- 3 Mid-Cap to Mega-Cap Stocks Have Announced Significant Buybacks
- The Basics of Support and Resistance
- These 3 Stocks Have Huge Last 12 Months Shareholder Yields
- What is a penny stock? A comprehensive guide
- Prominent Hedge Fund Acquires Huge Stake in HPE: Is It a Buy Now?
Receive News & Ratings for TransCode Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransCode Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
